Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 116,000 shares, a decline of 72.9% from the August 15th total of 427,700 shares. Currently, 5.0% of the company’s stock are short sold. Based on an average daily trading volume, of 795,400 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 795,400 shares, the short-interest ratio is currently 0.1 days. Currently, 5.0% of the company’s stock are short sold.
Hedge Funds Weigh In On Biomerica
An institutional investor recently bought a new position in Biomerica stock. Bulltick Wealth Management LLC bought a new position in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 137,149 shares of the company’s stock, valued at approximately $78,000. Bulltick Wealth Management LLC owned about 5.39% of Biomerica at the end of the most recent quarter. 22.28% of the stock is owned by institutional investors and hedge funds.
Biomerica Trading Up 1.0%
Shares of BMRA opened at $2.98 on Friday. The company has a market cap of $8.40 million, a price-to-earnings ratio of -1.28 and a beta of 0.35. Biomerica has a 1-year low of $2.08 and a 1-year high of $10.16. The company’s fifty day simple moving average is $3.22 and its 200 day simple moving average is $3.72.
Biomerica Company Profile
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Recommended Stories
- Five stocks we like better than Biomerica
- What Are Some of the Best Large-Cap Stocks to Buy?
- Tesla’s U.S. Market Is At An 8-Year Low… How Bad Could It Get?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Congress: The Biggest Trades Impacting Markets Today
- What is the Shanghai Stock Exchange Composite Index?
- 3 Companies Boosting Buybacks While Others Pull Back
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.